Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
2,877 results
  • [Pharmacological Treatment of Malignant Hyperthermia: Update 2019]. [Journal Article]
    Anasthesiol Intensivmed Notfallmed Schmerzther 2019; 54(9):549-558Schuster F, Johannsen S
  • Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle presenting as a hypermetabolic response to potent volatile anesthetics such as sevoflurane, desflurane, isoflurane and the depolarizing muscle relaxant succinylcholine. Following introduction of the hydantoin derivative dantrolene, the previously high mortality of fulminant MH episodes could be reduced from > 80% to less…
  • [Malignant Hyperthermia - Update on Pathophysiology, Diagnostics and Treatment]. [Journal Article]
    Anasthesiol Intensivmed Notfallmed Schmerzther 2019; 54(9):527-537Johannsen S, Schuster F
  • Malignant hyperthermia (MH) is a rare, heterogenic syndrome leading to potentially life-threatening skeletal muscle hypermetabolism following exposure to inhalational anesthetics and succinylcholine. In more than 50% of affected individuals a pathogenic variant in the RYR1 gene coding for the sarcoplasmic reticulum calcium channel is responsible for the underlying pathology of uncontrolled calciu…
  • Dantrolene Requires Mg2+ and ATP To Inhibit the Ryanodine Receptor. [Journal Article]
    Mol Pharmacol 2019; 96(3):401-407Diszházi G, Magyar ZÉ, … Almássy J
  • Dantrolene is a ryanodine receptor (RyR) inhibitor, which is used to relax muscles in malignant hyperthermia syndrome. Although dantrolene binds to the RyR protein, its mechanism of action is unknown, mainly because of the controversial results showing that dantrolene inhibited Ca2+ release from intact fibers and sarcoplasmic reticulum (SR) vesicles, but failed to inhibit single RyR channel curre…
New Search Next